This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

This study has been completed.
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
David Avigan, Beth Israel Deaconess Medical Center Identifier:
First received: February 21, 2008
Last updated: March 24, 2017
Last verified: March 2017
This study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.

Condition Intervention Phase
Metastatic Melanoma Biological: DC/tumor fusion vaccine Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

Resource links provided by NLM:

Further study details as provided by David Avigan, Beth Israel Deaconess Medical Center:

Primary Outcome Measures:
  • To assess the toxicity, cellular and humoral immunity and tumor response in patient with melanoma receiving the DC/tumor fusion vaccine [ Time Frame: screening/baseline, treatment period and follow-up ]

Estimated Enrollment: 20
Study Start Date: July 2000
Study Completion Date: September 10, 2008
Primary Completion Date: January 2002 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: DC/tumor fusion vaccine
    SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
Detailed Description:
To assess the toxicity associated with vaccination of melanoma patients with dendritic cell (DC)/tumor fusions. To determine if cellular and humoral immunity can be induced by serial vaccination with DC/tumor fusions cells. To determine if vaccination DC/tumor fusions results in a tumor response.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with confirmed diagnoses of disseminated melanoma, with measurable and clearly progressive metastatic involevment
  • Patients must be at least 18 years old
  • Patients must have ECOG performance status 0-1 with greater than 9 week life expectancy
  • Those patients with the following accessible tumor will be eligible: soft tissue, bone marrow or visceral lesions; Skin or superficial soft tissue, or lymph nodes amenable to resection under local anesthesia; Patients who require surgical procedures that are not considered significantly invasive but may require general anesthesia, such as thorascopic biopsy, laparascopic biopsy or mediastinal node biopsy may potentially be eligible; Malignant ascites or pleural effusion; Patients requiring major surgical intervention will be considered ineligible. Patients scheduled to undergo tumor resection for independent diagnostic or therapeutic indications may have tumor collected for the purposes of this study.
  • Labs: WBC >_ 2.0 x 10x3/uL, Bilirubin <_2.0 mg/dL, Creatine <_ 2.0mg/dL
  • Women of childbearing age must have a negative pregnancy test and adequate contraception method(s) must be documented
  • All patients must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines

Exclusion Criteria:

  • Patients must not have received other immunotherapy treatment in the past four weeks prior to study entry
  • Patients must not have received chemotherapy for three weeks prior to the first vaccination
  • Patients must be without evidence of active CNS disease
  • Patients must not have clinically significant autoimmune disease
  • Patients must be HIV negative
  • Patients must not have serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
  • Patients requiring corticosteroids for either melanoma related or co-morbid illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00626860

United States, Massachusetts
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Genzyme, a Sanofi Company
Principal Investigator: David Avigan, MD Beth Israel Deaconess Medical Center
  More Information

Responsible Party: David Avigan, Professor of Medicine, Beth Israel Deaconess Medical Center Identifier: NCT00626860     History of Changes
Other Study ID Numbers: 2001P001112
Study First Received: February 21, 2008
Last Updated: March 24, 2017

Keywords provided by David Avigan, Beth Israel Deaconess Medical Center:

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Immunologic Factors
Physiological Effects of Drugs processed this record on August 23, 2017